Longboard Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Longboard Pharmaceuticals

31/07/2023 12:15

* Longboard Pharmaceuticals Inc  LBPH.OQ   LBPH.O  is
expected
to show no change in quarterly revenue when it reports 
results on August 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Longboard
Pharmaceuticals
Inc is for a loss of 60 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Longboard
Pharmaceuticals Inc is $16​, above​ its last closing price
of $7.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.57       -0.57      -0.56     Beat    2.5
 Dec. 31 2023  -0.70       -0.69      -0.66     Beat    5
 Sep. 30 2022  -0.66       -0.64      -0.68     Missed  -6.9​
 Jun. 30 2022  -0.60       -0.57      -0.67     Missed  -17
 ​​Mar.        -0.58       -0.55      -0.56     Missed  -1.3
 31 2022                                                
 Dec. 31 2021  -0.42       -0.43      -0.52     Missed  -20.5​
 Sep. 30 2021  -0.47       -0.48      -0.38     Beat    20.1
 Jun. 30 2021  -0.67       -0.67      -0.41     Beat    39.1
 This summary was machine generated July 31 at 11:15 GMT.  All
figures in US dollars  unless otherwise stated